Hamsters immunized with either noninfectious hamster type-C virus (D9) or irradiated D9 tumor cells were tested for cell-mediated immune reactivity by the macrophage migration inhibition assay. The migration of peritoneal exudate cells from immunized hamsters was significantly inhibited by either D9 virus or D9 tumor extract, but not by extract of an unrelated CELO virus-induced tumor. The virus and tumor extracts had little or no effect on the migration of peritoneal exudate cells from normal hamsters. Noninfectious D9 virus produces a cellmediated immune response in the hamster and shares antigenicity with D9 lymphoma, which releases the virus.
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The D9 lymphoma is a transplantable tumor of the Syrian golden hamster (Mesocricetus auratus) and sheds a hamster-specific type-C virus (D9) into the blood of tumor-bearing animals (18, 19) . The virions are nononcogenic in vivo (19) and noninfectious in vitro (17) . Similar types of noninfectious type-C viruses have been reported both in murine (9, 12) and avian species (5, 16) . Although this class of virus particles may be present in each species, their biological significance is not known. Todaro (21) has postulated that activation of C-type virions may be a mechanism which induces an effective immune response against the development of tumor.
In an attempt to test the above hypothesis, we determined the ability of this noninfectious hamster-specific type-C virus to induce a cellmediated immune response in hamsters as measured by the mogenizing tumor fragments in 5 volumes of 3 M KCI in phosphate-buffered saline, followed by extraction in the same solution for 18 h at 4°C with gentle shaking (15) . The solution was centrifuged at 100,000 x g for 60 min at 4°C, and the supernatant was dialyzed against 200 volumes of phosphate-buffered saline for 48 h. The phosphate-buffered saline was changed at 8-h intervals. The dialyzed extract was then centrifuged at 40,000 x g for 60 min at 4°C and stored at -70°C until used. Tumor extracts were used in concentrations which did not inhibit migration of nornal peritoneal exudate cells (PEC).
D9 virus. Concentrated suspensions of D9 virus were prepared from plasma of D9-tumor-bearing animals. Infected plasma was clarified at 9,000 x g for 10 min. Plasma pellets were prepared by sedimentation at 78,000 x g for 1 h. The pellets were suspended in phosphate-buffered saline (pH 7.2) at '/A6 the original volume. The concentrated virus had an antigen titer of 1:512 per 0.025 ml as determined by inhibition of the passive hemagglutination test for Syrian hamster type-C antigens (6) . For control purposes, preparations of normal hamster plasma were made in a similar way.
Immunization. Hamsters, 6 to 8 weeks old, were immunized either by D9 virus or irradiated D9 cells (5,000 roentgen). D9 virus was mixed with an equal volume of Freund complete adjuvant (Difco Laboratories, Detroit, Mich.), and 0.1 ml was injected into the footpads of both hind feet and on either side of the back. This was followed by three consecutive subcutaneous inoculations at intervals of 10 to 14 days.
Immunizations with irradiated tumor cells (107 per hamster) were given subcutaneously or intraperitoneally once a week for 5 (25) and against MOPC-315 plasmacytoma by immunization with nononcogenic type-C virus particles prepared from ascitic fluid of plasmacytomabearing mice (7) also agrees with the concept. The discovery of type-C virus antigens, such as p30 and gp69/71, on the cell membrane of mouse tumors or murine sarcoma virus-transformed cells (20, 26) suggests the possible contribution of these viral antigens in the induction and monitoring of the immune response in the host. Therefore, a practical use of noninfectious virions may be in immunization against tumors producing the same or related viruses. Our study indicates that both virus and tumor share antigen(s), although whether the latter are viral or cellular remains to be determined. This suggests that a noninfectious virion may be employed as an immunogen against the development of homologous or related tumors. Further studies regarding the type(s) of antigen involved in the induction of cell-mediated immunity in the host must be done. In addition, we must determine whether this response can be induced during tumor growth without pre-sensitization by virus as reported here.
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